Drug safety in multiple sclerosis: From reporting to signal detection and benefit-risk management
CONCLUSION: Improvement of the PV system procedures has led to significant progress in the detection of signals, allowing better assessment of the benefit-risk balance and the implementation of risk management plans for MS treatments. The involvement of neurologists is essential to improve knowledge on the benefit-risk balance of these drugs. In addition, adverse drug reactions reporting by persons with MS should be encouraged.PMID:33812676 | DOI:10.1016/j.neurol.2021.01.009
Source: Revue Neurologique - Category: Neurology Authors: L Peyro-Saint-Paul S Fedrizzi G Defer Source Type: research
More News: Brain | CIDP | Clinical Trials | Drugs & Pharmacology | International Medicine & Public Health | Multiple Sclerosis | Neurology | WHO